Personalized therapy for breast cancer: A dream or a reality?

Future Oncology

Volumn 9, Issue 8, 2013, Pages 1105-1119

  Zardavas, Dimitrios ^a   Pugliano, Lina ^a   Piccart, Martine ^a,b  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

breast cancer; gene signature; molecular profiling; personalized medicine; targeted therapeutics

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AMG 888; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; APITOLISIB; AZD 2014; AZD 4547; AZD 5363; BMS 833923; BMS 906024; BUPARLISIB; BYL 719; CG 200745; COBIMETINIB; CRIZOTINIB; CUDC 101; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DNA METHYLTRANSFERASE INHIBITOR; DOXORUBICIN; DUSIGITUMAB; FLUOROURACIL; FULVESTRANT; GAMMA SECRETASE INHIBITOR; GDC 0068; GSK 2126458; GSK 2141795; HISTONE DEACETYLASE INHIBITOR; IMATINIB; INK 128; LAPATINIB; LEQ 506; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEDI 0639; MEHD 7945A; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MK 0752; MM 121; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NERATINIB; ONARTUZUMAB; PALBOCICLIB; PF 04449913; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PWT 33597; RABEPRAZOLE; SONIDEGIB; TAK 441; TAK 733; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB; XL 765;

BASAL LIKE BREAST CANCER; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STEM CELL; CANCER SUSCEPTIBILITY; CANCER THERAPY; CHEMOSENSITIVITY; CHRONIC MYELOID LEUKEMIA; CIRCULATING TUMOR CELL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HIGH RISK POPULATION; HIGH THROUGHPUT SEQUENCING; INTRACELLULAR SPACE; LASER CAPTURE MICRODISSECTION; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); METASTATIC MELANOMA; MONOTHERAPY; ONCOGENE C MYC; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SYSTEMIC THERAPY; TRIPLE NEGATIVE BREAST CANCER; VALIDATION STUDY;

BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84881282415     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.57     Document Type: Review

References (75)

1. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406 (6797), 747-752 (2000).
2. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100 (14), 8418-8423 (2003).
3. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98 (19), 10869-10874 (2001).
4. Sotiriou C, Neo S-Y, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. USA 100 (18), 10393-10398 (2003).
5. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360 (8), 790-800 (2009).
6. Collisson EA, Cho RJ, Gray JW. What are we learning from the cancer genome? Nat. Rev. Clin. Oncol. 9 (11), 621-630 (2012).
7. Desmedt C, Haibe-Kains B, Wirapati P et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14 (16), 5158-5165 (2008).
8. Reis-Filho JS, Weigelt B, Fumagalli D, Sotiriou C. Molecular profiling: Moving away from tumor philately. Sci. Transl Med. 2 (47), 47ps43 (2010).
9. Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10 (4), R65 (2008).
10. Desmedt C, Piette F, Loi S et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 13 (11), 3207-3214 (2007).
11. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: The MINDACT trial. J. Clin. Oncol. 26 (5), 729-735 (2008).
12. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26 (5), 721-728 (2008).
13. Finak G, Bertos N, Pepin F et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14 (5), 518-527 (2008).
14. Desmedt C, Majjaj S, Kheddoumi N et al. Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment. Clin. Cancer Res. 18 (4), 1004-1014 (2012).
15. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 8 (8), R157 (2007).
16. Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 12 (5), R85 (2010).
17. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24 (23), 3726-3734 (2006).
18. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol. 11 (1), 55-65 (2010).
19. Tang G, Shak S, Paik S et al. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. Breast Cancer Res. Treat. 127 (1), 133-142 (2011).
20. Straver ME, Glas AM, Hannemann J et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res. Treat. 119 (3), 551-558 (2010).
21. Desmedt C, Di Leo A, De Azambuja E et al. Multifactorial approach to predicting resistance to anthracyclines. J. Clin. Oncol. 29 (12), 1578-1586 (2011).
22. Li Y, Zou L, Li Q et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat. Med. 16 (2), 214-218 (2010).
23. Symmans WF, Hatzis C, Sotiriou C et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J. Clin. Oncol. 28 (27), 4111-4119 (2010).
24. Hatzis C, Pusztai L, Valero V et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305 (18), 1873-1881 (2011).
25. Banerji S, Cibulskis K, Rangel-Escareno C et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486 (7403), 405-409 (2012).
26. Ellis MJ, Ding L, Shen D et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486 (7403), 353-360 (2012).
27. Shah SP, Roth A, Goya R et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486 (7403), 395-399 (2012).
28. Stephens PJ, Tarpey PS, Davies H et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486 (7403), 400-404 (2012).
29. De Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 467 (7315), 543-549 (2010).
30. Weinstein IB. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297 (5578), 63-64 (2002).
31. Garnett MJ, Edelman EJ, Heidorn SJ et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483 (7391), 570-575 (2012).
32. Barretina J, Caponigro G, Stransky N et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483 (7391), 603-307 (2012).
33. Bernards R. It's diagnostics, stupid. Cell 141 (1), 13-17 (2010).
34. Berns K, Horlings HM, Hennessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12 (4), 395-402 (2007).
35. Iorns E, Turner NC, Elliott R et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13 (2), 91-104 (2008).
36. Zardavas D, Fumagalli D, Loi S. Phosphatidylinositol 3-kinase/AKT/ mammalian target of rapamycin pathway inhibition: A breakthrough in the management of luminal (ER+/HER2-) breast cancers? Curr. Opin. Oncol. 24 (6), 623-634 (2012).
37. Saal LH, Johansson P, Holm K et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl. Acad. Sci. USA 104 (18), 7564-7569 (2007).
38. Loi S, Haibe-Kains B, Majjaj S et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc. Natl Acad. Sci. USA 107 (22), 10208-10213 (2010).
39. Creighton CJ, Casa A, Lazard Z et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J. Clin. Oncol. 26 (25), 4078-4085 (2008).
40. O'Reilly KE, Rojo F, She Q-B et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66 (3), 1500-1508 (2006).
41. Nik-Zainal S, Van Loo P, Wedge DC et al. The life history of 21 breast cancers. Cell 149 (5), 994-1007 (2012).
42. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. Cancer 103 (8), 1139-1143 (2010).
43. Duncan JS, Whittle MC, Nakamura K et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149 (2), 307-321 (2012).
44. Bernards R. A missing link in genotype-directed cancer therapy. Cell 151 (3), 465-468 (2012).
45. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351 (8), 781-791 (2004).
46. De Giorgi U, Valero V, Rohren E et al. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann. Oncol. 21 (1), 33-39 (2010).
47. De Giorgi U, Valero V, Rohren E et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J. Clin. Oncol. 27 (20), 3303-3311 (2009).
48. De Giorgi U, Mego M, Rohren EM et al. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J. Nucl. Med. 51 (8), 1213-1218 (2010).
49. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11 (4), R46 (2009).
50. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 14 (1), R15 (2012).
51. Lianidou ES, Markou A, Strati A. Molecular characterization of circulating tumor cells in breast cancer: Challenges and promises for individualized cancer treatment. Cancer Metastasis Rev. 31 (3-4), 663-671 (2012).
52. Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers - blood-based strategies to detect and monitor cancer. Nat. Rev. Clin. Oncol. 8 (3), 142-150 (2011).
53. Leary RJ, Kinde I, Diehl F et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci. Transl Med. 2 (20), 20ra14 (2010).
54. McBride DJ, Orpana AK, Sotiriou C et al. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer 49 (11), 1062-1069 (2010).
55. Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, Liu G. Germline genetic variation, cancer outcome, and pharmacogenetics. J. Clin. Oncol. 28 (26), 4029-4037 (2010).
56. Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: A summary of evidence. Breast Cancer Res. Treat. 119 (1), 13-24 (2010).
57. O'Donnell PH, Ratain MJ. Germline pharmacogenomics in oncology: Decoding the patient for targeting therapy. Mol. Oncol. 6 (2), 251-259 (2012).
58. Hertz DL, McLeod HL, Irvin WJ Jr. Tamoxifen and CYP2D6: A contradiction of data. Oncologist 17 (5), 620-630 (2012).
59. Musolino A, Naldi N, Bortesi B et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26 (11), 1789-1796 (2008).
60. Ingle JN, Schaid DJ, Goss PE et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J. Clin. Oncol. 28 (31), 4674-4682 (2010).
61. Bates SE, Amiri-Kordestani L, Giaccone G. Drug development: Portals of discovery. Clin. Cancer Res. 18 (1), 23-32 (2012).
62. Verdine GL, Walensky LD. The challenge of drugging undruggable targets in cancer: Lessons learned from targeting BCL-2 family members. Clin. Cancer Res. 13 (24), 7264-7270 (2007).
63. De Palma M, Hanahan D. The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities. Mol. Oncol. 6 (2), 111-127 (2012).
64. Buyse M, Sargent DJ, Grothey A, Matheson A, De Gramont A. Biomarkers and surrogate end points - the challenge of statistical validation. Nat. Rev. Clin. Oncol. 7 (6), 309-317 (2010).
65. Westfall JM, Mold J, Fagnan L. Practice-based research - "Blue Highways" on the NIH roadmap. JAMA 297 (4), 403-406 (2007).
66. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J. Clin. Oncol. 25 (2), 209-216 (2007).
67. Gianni L, Pienkowski T, Im Y-H et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, Phase 2 trial. Lancet Oncol. 13 (1), 25-32 (2012).
68. Baselga J, Cortés J, Kim S-B et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366 (2), 109-119 (2012).
69. Melese T, Lin SM, Chang JL, Cohen NH. Open innovation networks between academia and industry: An imperative for breakthrough therapies. Nat. Med. 15 (5), 502-507 (2009).
70. Pugliano L, Fumagalli D, Irrthum A et al. Integrate: A new model in collaborative breast cancer research. Presented at: Advanced Breast Cancer Conference 1. Lisbon, Portugal, 3-5 November 2011 (Poster PO43).
71. Oestreicher N, Ramsey SD, Linden HM et al. Gene expression profiling and breast cancer care: What are the potential benefits and policy implications? Genet. Med. 7 (6), 380-389 (2005).
72. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am. J. Manag. Care 11 (5), 313-324 (2005).
73. Lo SS, Mumby PB, Norton J et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J. Clin. Oncol. 28 (10), 1671-1676 (2010).
74. Greaves M, Maley CC. Clonal evolution in cancer. Nature 481 (7381), 306-313 (2012).
75. Bendall SC, Nolan GP. From single cells to deep phenotypes in cancer. Nat. Biotechnol. 30 (7), 639-647 (2012).